Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Genotype frequencies by treatment group

From: Red clover-derived isoflavones and mammographic breast density: a double-blind, randomized, placebo-controlled trial [ISRCTN42940165]

  Group  
Gene/polymorphism Isoflavone Placebo P
CYP17a    
   TT 32 (40%) 33 (39%)  
   TC 36 (44%) 40 (47%) 0.92
   CC 13 (16%) 12 (14%)  
CYP19b    
   GG 21 (27%) 28 (32%)  
   GT 40 (51%) 45 (52%) 0.49
   TT 18 (23%) 14 (16%)  
ESR1c    
   CC 17 (22%) 19 (22%)  
   CT 39 (51%) 46 (53%) 0.95
   TT 21 (27%) 22 (25%)  
  1. aCYP17 data not available for three and five women in the isoflavone and placebo groups, respectively. bCYP19 data not available for five and three women in the isoflavone and placebo groups, respectively. cESR1 data not available for seven and three women in the isoflavone and placebo groups, respectively. Percentages do not always add up to 100% because of rounding.